BioGeneriX exercised its option for the development of a long-acting, next generation version of a therapeutic protein using Neose’s enzymatic GlycoPEGylation(TM) technology. This deal also grants BioGeneriX an exclusive worldwide license to use the technology to develop and commercialize the therapeutic protein.